Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Pyrazole and imidazo[1,2-b]pyrazole Derivatives as New Potential Antituberculosis Agents.

Meta E, Brullo C, Tonelli M, Franzblau SG, Wang Y, Ma R, Baojie W, Orena BS, Pasca MR, Bruno O.

Med Chem. 2019;15(1):17-27. doi: 10.2174/1573406414666180524084023.

PMID:
29792151
2.

Molecular Bases of PDE4D Inhibition by Memory-Enhancing GEBR Library Compounds.

Prosdocimi T, Mollica L, Donini S, Semrau MS, Lucarelli AP, Aiolfi E, Cavalli A, Storici P, Alfei S, Brullo C, Bruno O, Parisini E.

Biochemistry. 2018 May 15;57(19):2876-2888. doi: 10.1021/acs.biochem.8b00288. Epub 2018 May 1.

PMID:
29652483
3.

An Update on JAK Inhibitors.

Musumeci F, Greco C, Giacchello I, Fallacara AL, Ibrahim MM, Grossi G, Brullo C, Schenone S.

Curr Med Chem. 2019;26(10):1806-1832. doi: 10.2174/0929867325666180327093502. Review.

PMID:
29589523
4.

The pyrazolyl-urea GeGe3 inhibits tumor angiogenesis and reveals dystrophia myotonica protein kinase (DMPK)1 as a novel angiogenesis target.

Meta E, Imhof BA, Ropraz P, Fish RJ, Brullo C, Bruno O, Sidibé A.

Oncotarget. 2017 Nov 21;8(64):108195-108212. doi: 10.18632/oncotarget.22598. eCollection 2017 Dec 8.

5.

Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease.

Ricciarelli R, Brullo C, Prickaerts J, Arancio O, Villa C, Rebosio C, Calcagno E, Balbi M, van Hagen BT, Argyrousi EK, Zhang H, Pronzato MA, Bruno O, Fedele E.

Sci Rep. 2017 Apr 12;7:46320. doi: 10.1038/srep46320.

6.

Design, synthesis and biological evaluation of new pyrazolyl-ureas and imidazopyrazolecarboxamides able to interfere with MAPK and PI3K upstream signaling involved in the angiogenesis.

Meta E, Brullo C, Sidibe A, Imhof BA, Bruno O.

Eur J Med Chem. 2017 Jun 16;133:24-35. doi: 10.1016/j.ejmech.2017.03.066. Epub 2017 Mar 27.

PMID:
28371678
7.

Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.

Musumeci F, Sanna M, Grossi G, Brullo C, Fallacara AL, Schenone S.

Curr Med Chem. 2017;24(19):2059-2085. doi: 10.2174/0929867324666170303162100. Review.

PMID:
28266267
8.

Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.

Musumeci F, Fallacara AL, Brullo C, Grossi G, Botta L, Calandro P, Chiariello M, Kissova M, Crespan E, Maga G, Schenone S.

Eur J Med Chem. 2017 Feb 15;127:369-378. doi: 10.1016/j.ejmech.2016.12.036. Epub 2016 Dec 19.

PMID:
28076826
9.

New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment.

Brullo C, Ricciarelli R, Prickaerts J, Arancio O, Massa M, Rotolo C, Romussi A, Rebosio C, Marengo B, Pronzato MA, van Hagen BTJ, van Goethem NP, D'Ursi P, Orro A, Milanesi L, Guariento S, Cichero E, Fossa P, Fedele E, Bruno O.

Eur J Med Chem. 2016 Nov 29;124:82-102. doi: 10.1016/j.ejmech.2016.08.018. Epub 2016 Aug 13.

PMID:
27560284
10.

Analogs, formulations and derivatives of imatinib: a patent review.

Musumeci F, Schenone S, Grossi G, Brullo C, Sanna M.

Expert Opin Ther Pat. 2015;25(12):1411-21. doi: 10.1517/13543776.2015.1089233. Epub 2015 Sep 15. Review.

PMID:
26372795
11.

Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors.

Brullo C, Massa M, Villa C, Ricciarelli R, Rivera D, Pronzato MA, Fedele E, Barocelli E, Bertoni S, Flammini L, Bruno O.

Bioorg Med Chem. 2015 Jul 1;23(13):3426-35. doi: 10.1016/j.bmc.2015.04.027. Epub 2015 Apr 16.

PMID:
25936260
12.

Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors.

Tintori C, La Sala G, Vignaroli G, Botta L, Fallacara AL, Falchi F, Radi M, Zamperini C, Dreassi E, Dello Iacono L, Orioli D, Biamonti G, Garbelli M, Lossani A, Gasparrini F, Tuccinardi T, Laurenzana I, Angelucci A, Maga G, Schenone S, Brullo C, Musumeci F, Desogus A, Crespan E, Botta M.

J Med Chem. 2015 Jun 11;58(11):4590-609. doi: 10.1021/acs.jmedchem.5b00140. Epub 2015 May 20.

PMID:
25923950
13.

Bcr-Abl tyrosine kinase inhibitors: a patent review.

Desogus A, Schenone S, Brullo C, Tintori C, Musumeci F.

Expert Opin Ther Pat. 2015 Apr;25(4):397-412. doi: 10.1517/13543776.2015.1012155. Epub 2015 Feb 6. Review.

PMID:
25656651
14.

Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.

Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M.

J Med Chem. 2015 Jan 8;58(1):347-61. doi: 10.1021/jm5013159. Epub 2014 Dec 3.

PMID:
25469771
15.

Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.

Brullo C, Massa M, Rocca M, Rotolo C, Guariento S, Rivera D, Ricciarelli R, Fedele E, Fossa P, Bruno O.

J Med Chem. 2014 Aug 28;57(16):7061-72. doi: 10.1021/jm500855w. Epub 2014 Aug 15.

PMID:
25126889
16.

Biologically driven synthesis of pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors: an old scaffold as a new tool for medicinal chemistry and chemical biology studies.

Schenone S, Radi M, Musumeci F, Brullo C, Botta M.

Chem Rev. 2014 Jul 23;114(14):7189-238. doi: 10.1021/cr400270z. Epub 2014 May 29. Review. No abstract available.

PMID:
24873489
17.

Differential inhibition of signaling pathways by two new imidazo-pyrazoles molecules in fMLF-OMe- and IL8-stimulated human neutrophil.

Selvatici R, Brullo C, Bruno O, Spisani S.

Eur J Pharmacol. 2013 Oct 15;718(1-3):428-34. doi: 10.1016/j.ejphar.2013.07.045. Epub 2013 Aug 23.

PMID:
23978569
18.

Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents.

Tintori C, Laurenzana I, La Rocca F, Falchi F, Carraro F, Ruiz A, Esté JA, Kissova M, Crespan E, Maga G, Biava M, Brullo C, Schenone S, Botta M.

ChemMedChem. 2013 Aug;8(8):1353-60. doi: 10.1002/cmdc.201300204. Epub 2013 Jun 28.

PMID:
23813855
19.

Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant.

Radi M, Tintori C, Musumeci F, Brullo C, Zamperini C, Dreassi E, Fallacara AL, Vignaroli G, Crespan E, Zanoli S, Laurenzana I, Filippi I, Maga G, Schenone S, Angelucci A, Botta M.

J Med Chem. 2013 Jul 11;56(13):5382-94. doi: 10.1021/jm400233w. Epub 2013 Jun 20.

PMID:
23746084
20.

A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors.

Mori M, Tintori C, Christopher RS, Radi M, Schenone S, Musumeci F, Brullo C, Sanità P, Delle Monache S, Angelucci A, Kissova M, Crespan E, Maga G, Botta M.

ChemMedChem. 2013 Mar;8(3):484-96. doi: 10.1002/cmdc.201200480.

PMID:
23436791

Supplemental Content

Loading ...
Support Center